CAPA E LOMBADA - Arca - Fiocruz

113
Wang JT, Wang TH, Sheu JC, Lin JT, Chen DS. Hepatitis C virus RNA in saliva
of patients with posttransfusion hepatitis and low efficiency of transmission
among spouses. J Med Virol 1992; 36(1): 28. (Resumo)
Watson JD, Crick FHC. Molecular Structure of Nucleic Acids. Nature 1953;
171 (4356): 737-738.
Weinberg JM, Saini R, Tutrone WD. Biologic therapy for psoriasis – the first
wave: infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol
2002; 1(3): 303-310.
Werner RG. Economic aspects of commercial manufacture of
biopharmaceuticals. J Biotechnol 2004; 113: 171-182.
WHO (World Health Organization). Informal Consultation on Regulatory
Evaluation of Therapeutic Biological Medicinal Products. Geneva: WHO;
2007.
______. Guidelines for the production and quality control of candidate
tetravalent dengue virus vaccines (live). Annex 1. Geneva: WHO 2006; 932.
______. Requirements for the use of animal cells as in vitro substrates for
the production of biologicals – Annex 4 (Addedum 2003). Geneva: WHO
2005; 927.
______. Recommendations and guidelines for biological substances used in
medicine and other documents (Annex 6). Geneva: WHO 2004a; 924.
______. WHO Expert Committee on Biological Standardization. Fifty-third
Report. Geneva: WHO 2004b; 926.
______. Regulating biotechnology products. Geneva: ICDRA; 2003.
______. Recommendations for the production and control of poliomyelitis
vaccine (inactivated). Geneva: WHO 2002; 910.
______. Hepatitis C. [online]. Geneva; 2000 [capturado 17 fev 2009] Disponível
em: http://www.who.int/mediacentre/factsheets/fs164/en/